Characteristics and prognostic factor in patients with advanced renal cell carcinoma (RCC) achieving complete response by treatment using biological response modifiers (BRM)

K. Marumo, Y. Huang, Mototsugu Oya, M. Tachibana, M. Murai, H. Tazaki

Research output: Contribution to journalArticle

Abstract

One of 24 patients treated with human lymphoblastoid interferon (IFN), 2 of 20 patients treated by sequential administration of IFN and OK-432, and 3 of 18 patients treated with interleukin 2 achieved a complete response. All 6 patients had been nephrectomized, and had a common type of renal cell carcinoma. Metastatic sites were lung and mediastinum in one patient and lung alone in the other 5 patients. Five of 6 patients developed a recurrence between 11 months and 6 years of disease-free periods and did not respond to primarily effective therapy. The results demonstrated that careful observation is needed even after disappearance of a tumor by treatment with BRMs and establishment of a new modality for recurrent RCD was encouraged.

Original languageEnglish
Pages (from-to)554-556
Number of pages3
JournalBiotherapy
Volume10
Issue number3
Publication statusPublished - 1996

Fingerprint

Immunologic Factors
Renal Cell Carcinoma
Therapeutics
Picibanil
Lung
Mediastinum
Interferon-alpha
Interferons
Interleukin-2
Observation
Recurrence
Neoplasms

Keywords

  • Complete response
  • Interferon
  • Interleukin 2
  • OK-432
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Characteristics and prognostic factor in patients with advanced renal cell carcinoma (RCC) achieving complete response by treatment using biological response modifiers (BRM). / Marumo, K.; Huang, Y.; Oya, Mototsugu; Tachibana, M.; Murai, M.; Tazaki, H.

In: Biotherapy, Vol. 10, No. 3, 1996, p. 554-556.

Research output: Contribution to journalArticle

@article{af225f5532b14a4aa919abc320460fdb,
title = "Characteristics and prognostic factor in patients with advanced renal cell carcinoma (RCC) achieving complete response by treatment using biological response modifiers (BRM)",
abstract = "One of 24 patients treated with human lymphoblastoid interferon (IFN), 2 of 20 patients treated by sequential administration of IFN and OK-432, and 3 of 18 patients treated with interleukin 2 achieved a complete response. All 6 patients had been nephrectomized, and had a common type of renal cell carcinoma. Metastatic sites were lung and mediastinum in one patient and lung alone in the other 5 patients. Five of 6 patients developed a recurrence between 11 months and 6 years of disease-free periods and did not respond to primarily effective therapy. The results demonstrated that careful observation is needed even after disappearance of a tumor by treatment with BRMs and establishment of a new modality for recurrent RCD was encouraged.",
keywords = "Complete response, Interferon, Interleukin 2, OK-432, Renal cell carcinoma",
author = "K. Marumo and Y. Huang and Mototsugu Oya and M. Tachibana and M. Murai and H. Tazaki",
year = "1996",
language = "English",
volume = "10",
pages = "554--556",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "3",

}

TY - JOUR

T1 - Characteristics and prognostic factor in patients with advanced renal cell carcinoma (RCC) achieving complete response by treatment using biological response modifiers (BRM)

AU - Marumo, K.

AU - Huang, Y.

AU - Oya, Mototsugu

AU - Tachibana, M.

AU - Murai, M.

AU - Tazaki, H.

PY - 1996

Y1 - 1996

N2 - One of 24 patients treated with human lymphoblastoid interferon (IFN), 2 of 20 patients treated by sequential administration of IFN and OK-432, and 3 of 18 patients treated with interleukin 2 achieved a complete response. All 6 patients had been nephrectomized, and had a common type of renal cell carcinoma. Metastatic sites were lung and mediastinum in one patient and lung alone in the other 5 patients. Five of 6 patients developed a recurrence between 11 months and 6 years of disease-free periods and did not respond to primarily effective therapy. The results demonstrated that careful observation is needed even after disappearance of a tumor by treatment with BRMs and establishment of a new modality for recurrent RCD was encouraged.

AB - One of 24 patients treated with human lymphoblastoid interferon (IFN), 2 of 20 patients treated by sequential administration of IFN and OK-432, and 3 of 18 patients treated with interleukin 2 achieved a complete response. All 6 patients had been nephrectomized, and had a common type of renal cell carcinoma. Metastatic sites were lung and mediastinum in one patient and lung alone in the other 5 patients. Five of 6 patients developed a recurrence between 11 months and 6 years of disease-free periods and did not respond to primarily effective therapy. The results demonstrated that careful observation is needed even after disappearance of a tumor by treatment with BRMs and establishment of a new modality for recurrent RCD was encouraged.

KW - Complete response

KW - Interferon

KW - Interleukin 2

KW - OK-432

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0029867283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029867283&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029867283

VL - 10

SP - 554

EP - 556

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -